Related Experiment Videos
Gene therapy for brain tumors
C M Kramm1, M Sena-Esteves, F H Barnett
1Neuroscience Center, Massachusetts General Hospital, USA.
Abstract:
Gene therapy has opened new doors for treatment of neoplastic diseases. This new approach seems very attractive, especially for glioblastomas, since treatment of these brain tumors has failed using conventional therapy regimens. Many different modes of gene therapy for brain tumors have been tested in culture and in vivo. Many of these approaches are based on previously established anti-neoplastic principles, like prodrug activating enzymes, inhibition of tumor neovascularization, and enhancement of the normally weak anti-tumor immune response. Delivery of genes to tumor cells has been mediated by a number of viral and synthetic vectors. The most widely used paradigm is based on the activation of ganciclovir to a cytotoxic compound by a viral enzyme, thymidine kinase, which is expressed by tumor cells, after the gene has been introduced by a retroviral vector. This paradigm has proven to be a potent therapy with minimal side effects in several rodent brain tumor models, and has proceeded to phase 1 clinical trials. In this review, current gene therapy strategies and vector systems for treatment of brain tumors will be described and discussed in light of further developments needed to make this new treatment modality clinically efficacious.
Insights
Gene therapy offers a promising new avenue for treating brain tumors like glioblastomas, especially when conventional methods fail. Viral vector delivery systems show potential for effective treatment with minimal side effects.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Conventional therapies often fail for aggressive brain tumors such as glioblastomas.
- Gene therapy presents a novel therapeutic strategy for neoplastic diseases.
Purpose of the Study:
- To review current gene therapy strategies for brain tumors.
- To discuss vector systems and their efficacy in preclinical and clinical settings.
Main Methods:
- Exploration of gene therapy principles including prodrug activation, anti-angiogenesis, and immune enhancement.
- Evaluation of viral and synthetic vectors for gene delivery to tumor cells.
- Focus on the thymidine kinase/ganciclovir system delivered via retroviral vectors.
Main Results:
- The thymidine kinase/ganciclovir gene therapy paradigm demonstrated potent efficacy with minimal side effects in rodent brain tumor models.
- This approach has advanced to phase 1 clinical trials.
Conclusions:
- Gene therapy holds significant promise for treating brain tumors, particularly glioblastomas.
- Further development is required to optimize gene therapy vector systems for clinical efficacy.